![]() | |
Clinical data | |
---|---|
Trade names | Acofide |
Other names | YM-443, Z-338 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 84.21–85.95% |
Metabolism | UGT1A8 and 1A9 (major) |
Elimination half-life | 10.9–21.7 hours |
Excretion | Feces (92.7%), urine (5.3%) [1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H30N4O5S |
Molar mass | 450.55 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Acotiamide, sold under the brand name Acofide, [2] [3] is a medication manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. [4] It acts as an acetylcholinesterase inhibitor.
![]() | |
Clinical data | |
---|---|
Trade names | Acofide |
Other names | YM-443, Z-338 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 84.21–85.95% |
Metabolism | UGT1A8 and 1A9 (major) |
Elimination half-life | 10.9–21.7 hours |
Excretion | Feces (92.7%), urine (5.3%) [1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H30N4O5S |
Molar mass | 450.55 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Acotiamide, sold under the brand name Acofide, [2] [3] is a medication manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. [4] It acts as an acetylcholinesterase inhibitor.